The results of 21-year experience of treating anal squamous cell carcinomas

Abstract

Objective: Anal squamous cell carcinomas are one of the rare cancer types. Due to the developments in the past 35 years, surgery is no longer the first treatment of choice. The aim of this study was to retrospectively examine the outcomes of 24 patients treated in a single center in the last 21 years in terms of applied treatment, local relapse, distant metastasis, post-treatment complications, and survival. Material and Methods:Data obtained from 24 anal squamous cell carcinoma patients, who were treated in Ankara Oncology Research and Education Hospital between 1990 and 2010, were retrospectively evaluated. Results:Of the 24 patients, 16 had anal canal squamous cell carcinoma and eight had perianal squamous cell carcinoma. All of the patients with anal canal squamous cell carcinoma (n=16) received chemoradiotherapy. Three of these patients who did not respond to treatment, underwent abdominoperineal resection. The patients with perianal squamous cell tumors were treated by local excision. During the follow -ups, seven patients experienced local relapse, and one patient had distant organ metastasis. Only one patient died. Five-year disease free survival rate was found as 66%. Conclusion:Our findings suggest that the first alternative in the treatment of anal squamous cell tumors should be chemoradiotherapy; and surgery seems to be the appropriate approach for the non-responsive and relapsing cases.

Prognostic Significance of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography in Anal Squamous Cell Carcinoma: A Systematic Review and a Meta-Analysis

“…Haematogenous spread is rare at the time of diagnosis, but 40% of deaths during the course of the disease are due to distant metastases [7]. Anal carcinomas are categorized according to the TNM staging system [5]. The most important prognostic factors for anal cancer are known to be the tumor size and extent (T) and nodal involvement (N) [6].…”

“…In the absence of significant toxicity, consolidation chemotherapy is continued either for a predefined time period or until evidence of tumor progression is noted [9]. Surgical treatment is solely considered in relapsed cases or cases with no response to chemoradiotherapy [5, 10]. Adoption of such a therapeutic approach for locally advanced anal SCC has led to a 5-year OS ranging from 61% to 85%.…”

Condiloma gigante de Buschke-Lowenstein: um relato de caso

“…Isso faz com que a excisão cirúrgica completa seja o tratamento de escolha, 7,9,11,12 ressaltando-se que a radioterapia e a quimioterapia também podem ser empregadas para evitar que o cancro se estenda para o canal anal. Em um estudo de seguimento realizado por 21 anos em 24 pacientes diagnosticados com CEC anal e tratados, 8 pacientes foram tratados com ampla excisão local e nesses não foram detectadas nem recorrência, nem mortalidade, dado consistente com a literatura.…”

“…Em um estudo de seguimento realizado por 21 anos em 24 pacientes diagnosticados com CEC anal e tratados, 8 pacientes foram tratados com ampla excisão local e nesses não foram detectadas nem recorrência, nem mortalidade, dado consistente com a literatura. 9 Ressalta-se que não há dados disponíveis suficientes para recomendar o tratamento como radioterapia, quimioterapia ou interferon, sendo esses apenas paliativos. 11 Todavia, no caso descrito, apesar de tratamento com ampla excisão cirúrgica em poucos meses de pós-operató-rio, observou-se recorrência.…”

“…Os fatores de risco envolvem infecção pelo HIV, infecção por HPV, imunodeficiência, sexo anal e história de câncer cérvico-vaginal-vulvar. 9 O diagnóstico de câncer da região anal geralmente é feito por exame físico e retoscopia. Em 15 a 20% dos casos, metástases em linfonodos regionais estão presentes já quando se dá o diagnóstico.…”